Vaccines play a critical role in fighting pandemics, and while several COVID-19 vaccines are available, more options are needed to ensure protection for all patient groups. Inactivated vaccines, like those used for rabies, polio, and hepatitis A, have a strong safety profile and a long history of success.
Valneva, a specialty vaccine company, has developed an inactivated, dual-adjuvanted whole virus vaccine for COVID-19. Unlike mRNA or vector-based vaccines, this vaccine contains the entire SARS-CoV-2 virus, which has been grown in a controlled cell culture, purified, and inactivated while maintaining the virus’s natural structure. Since the virus is inactivated, it cannot replicate or cause illness.
To enhance the immune response, Valneva’s vaccine includes two adjuvants, similar to those found in other approved vaccines. This combination boosts immunity, leading to a strong neutralizing antibody response. Additionally, the vaccine is designed to be stored at standard refrigerator temperatures, simplifying distribution and accessibility.
As a European-manufactured vaccine, Valneva’s innovation provides a well-tolerated, traditional alternative to newer vaccine technologies. Learn more at valneva.com.
